The Relationship Between the Residual Renal Function and Osteoporosis Treatment

Toshihiko Kono1,000 enrolled

Overview

The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.

Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear. The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Osteoporosis

Interventions

Bis, SERM Teriparatide, DenosumabDRUG

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Osteoporosis patients Exclusion Criteria: * eGFR \< 15

Locations (1)

Tomidahama Hospital

Yokkaichi, Mie-ken, Japan

RECRUITING

Outcomes

Primary Outcomes

Longitudinal renal function changes by osteoporotic treatment

Time frame: Up to 120 months

Central Contacts

Rui Niimi, MD

CONTACT

(81)-59-365-0023 furikakefuri@hotmail.co.jp

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.